Literature DB >> 8118387

Evaluation of oncogene-related proteins in serum.

J L Weissfeld1, R D Larsen, H L Niman, L H Kuller.   

Abstract

We hypothesize that the products of cellular oncogenes and antioncogenes are biomarkers of events related to cancer risk. This study uses monoclonal antibody technology to examine serum proteins which are immunologically related to ras oncogene and epidermal growth factor receptor proteins. We measured the prevalence of ras- and epidermal growth factor receptor-related proteins in stored and freshly frozen serum from cancer patients, male heavy smokers, and older healthy subjects. Work emphasized the attainment of inter- and intraobserver agreement between independent readings of immunoblot gels. Although we achieved acceptable levels of agreement, we uncovered evidence for blood collection and storage artifacts. Accounting for these artifacts, we compared 80 cancer patients and 188 middle-aged and older community controls and found a strong relationship (odds ratio = 11.1; 95% confidence interval, 6.0-20.6) between cancer and a M(r) 21,000 serum protein related to the ras oncogene product. These results indicate the need and importance of comprehensive pretesting of putative cancer biomarkers before use in applied or etiological epidemiological research.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8118387

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  4 in total

1.  Tobacco smoke: chemical carcinogenesis and genetic lesions.

Authors:  J L Cook
Journal:  Ochsner J       Date:  1999-07

Review 2.  Biomarkers of gene expression: growth factors and oncoproteins.

Authors:  P W Brandt-Rauf
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

3.  p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.

Authors:  J Schneider; P Presek; A Braun; P Bauer; N Konietzko; B Wiesner; H J Woitowitz
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

4.  Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.

Authors:  Malgorzata Banys-Paluchowski; Tanja Fehm; Wolfgang Janni; Bahriye Aktas; Peter A Fasching; Sabine Kasimir-Bauer; Karin Milde-Langosch; Klaus Pantel; Brigitte Rack; Sabine Riethdorf; Erich-Franz Solomayer; Isabell Witzel; Volkmar Müller
Journal:  BMC Cancer       Date:  2018-05-08       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.